Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,760 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #1 Clear all

Conditions: Healthy, Health Care Worker Patient Transmission, Aging
Interventions: PreserVision AREDS formulation soft gels or tablets, Multivitamin with 11mg of zinc; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 2,700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Neoplasms
Interventions: Niraparib Tablet, Niraparib Capsule; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 16
States / cities: Encinitas, California • Fresno, California • Denver, Colorado + 13 more

Conditions: HIV Infections
Interventions: VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20; Biological · Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 43
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 35 more

Conditions: Allergic Rhinitis
Interventions: placebo, isotonic ciclesonide, hypotonic ciclesonide; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Kidney Disease
Interventions: Zibotentan (Treatment A), Dapagliflozin (Treatment A), Zibotentan/Dapagliflozin - Formulation 1 (Treatment B), Zibotentan/Dapagliflozin - Formulation 2 (Treatment C); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Autism, Autism Spectrum Disorder
Interventions: Epidiolex, placebo oral solution; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 7 Years to 14 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Chronic Pain, Pain
Interventions: Medical Cannabis; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Overweight, Obesity
Interventions: Formulation A (PF-07081532 20 mg plus 60 mg), Formulation B (PF-07081532 80 mg); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Ocular Hyperemia
Interventions: Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, Vehicle; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Northbrook, Illinois • Garner, North Carolina • Shelby, North Carolina + 2 more

Conditions: Pharmacokinetics of Solifenacin Succinate, Healthy Volunteers
Interventions: Solifenacin Succinate Formulation A, Solifenacin Succinate Formulation B, Solifenacin Succinate; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Glaucoma, Ocular Hypertension
Interventions: Formulation E1 of L-PPDS, Formulation E2 of L-PPDS; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Solid Tumors
Interventions: AZD8055; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Ulcerative Colitis
Interventions: Granulated mesalamine, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Bristol, Connecticut

Conditions: Parkinson's Disease
Interventions: fipamezole; Drug
Lead sponsor: Juvantia Pharma Ltd; Industry
Eligibility: 30 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 29
States / cities: Birmingham, Alabama • Northport, Alabama • Tucson, Arizona + 25 more

Conditions: Influenza
Interventions: Influenza Virus Vaccine (2006-2007 Fluzone® vaccine); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Normal Ocular Health
Interventions: AC-170 0.17%, AC-170 0.24% (Formulation 1), AC-170 0.24% (Formulation 2), Olopatadine hydrochloride 0.2%/Tears Naturale II; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Healthy Participants
Interventions: Nintedanib, BMS 986278; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Osteoarthritis of the Knee
Interventions: TLC599, DSP; Drug
Lead sponsor: Taiwan Liposome Company; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 7
States / cities: Phoenix, Arizona • Miami, Florida • Charleston, South Carolina + 2 more

Conditions: Healthy
Interventions: Decitabine; Drug
Lead sponsor: EpiDestiny, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Epilepsy
Interventions: ataluren, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 2 Years to 12 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
Interventions: AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab; Drug
Lead sponsor: Aminex Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 20
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more

Conditions: Pre Diabetic
Interventions: Placebo, NM504:; Drug
Lead sponsor: NuMe Health; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Overactive Bladder
Interventions: onaBoNT-A, Oxybutynin ER; Drug
Lead sponsor: Christopher Patrick Smith; Other
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Houston, Texas

Search by objective public record fields.

Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19

Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

A Pilot Investigation of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray

Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism

Can Medical Cannabis Affect Opioid Use?

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults

A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation

A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG

Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes

A Study of Tor Kinase Inhibitor in Advanced Tumors

Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis

Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease

Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine

A Comparison of the Safety and Comfort of AC-170

A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants

A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee

Effect of Food on the Pharmacokinetics of Decitabine/Tetrahydrouridine Combination Capsules in Healthy Adult Subjects

Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

A Pilot Study to Determine the Effect of a Cobiotic Formulation on the Gastrointestinal Microbiome

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER